A Phase 1 interventional study of AVL-102 Injection in CIN 2/3 and HPV Infections, sponsored by Beijing Xunsheng Biomedical Research Co., Ltd.. Recruiting at 1 site in China. Open to female participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Beijing Xunsheng Biomedical Research Co., Ltd. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 67 studies in Papillomavirus Infections with a site in China — 25 open to participants now, 38 under way, 10 of them phase 3. Papillomavirus Infections · China.
Among the 67 studies in Papillomavirus Infections with a site in China, this one is the 43rd largest by planned enrollment of the 43 interventional ones that give a count, is one of 7 that started in 2026, is one of 8 in phase 1, reaches primary completion later than 23 of the 37 other live ones, and was the 66th registered.
580 studies on the registry are indexed under Papillomavirus Infections; 133 are open to participants now.
Browse Papillomavirus Infections studies →25 of the 67 studies in Papillomavirus Infections with a site in China are open now. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in China
Ages 10–45 · Women only · Healthy volunteers
Shanghai Mianyi Biopharmaceutical Co., Ltd. · Sites in China
Ages 18–55 · Women only
Second Affiliated Hospital, Zhejiang University, School of Medicine · Sites in China
Ages 25–65 · Women only · Healthy volunteers
The First Hospital of Jilin University · Sites in China
Ages 26–65 · Women only
Shanghai Bovax Biotechnology Co., Ltd. · Sites in China
Ages 9–45 · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 87 Papillomavirus Infections studies recruiting now, 38 (44%) set no upper age limit and 44 (51%) stop at 75 or younger; 19 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 64 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
67 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 9 · Phase 3 18 · Phase 4 3
First in 2005; this study’s year is marked. 7 started in 2026.
This study's planned enrollment of 12 is below the median of 229 across 404 interventional studies indexed under Papillomavirus Infections.
Median enrollment 540 across the 43 interventional studies, 2,600 across the 24 observational. Of the 18 that completed or were terminated, 5 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 67 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Beijing Xunsheng Biomedical Research Co., Ltd. as lead sponsor.
Beijing Xunsheng Biomedical Research Co., Ltd. has 1 study filed under Papillomavirus Infections — fewer than ten, so there is no comparison to draw.
5 of the studies in Papillomavirus Infections with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07833852Shanghai Zerun Biotechnology Co.,LtdLong-Term Immune Persistence After Bivalent HPV Vaccination in Females From Study 311-HPV-1005 | 2026-12 |
| NCT06137352Fujian Maternity and Child Health HospitalTwo Domestic HPV Vaccines and Imported HPV Vaccines in Women Aged 13-14 Years Study on Immunogenicity | 2026-12-31 |
| NCT07820241Shanghai Zerun Biotechnology Co.,LtdLong-term Immune Persistence of a Bivalent HPV Vaccine in Females From Study 311-HPV-1004 | 2027-04 |
| NCT05371353Shanghai Bovax Biotechnology Co., Ltd.Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine | 2027-05 |
| NCT07942779Beijing Xunsheng Biomedical Research Co., Ltd.AVL-102 for the Treatment of HPV 16/18/52/58-Related High-Grade Lesions | 2027-07-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 67 studies in Papillomavirus Infections with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study was designed to evaluate the safety, tolerability, and efficacy of AVL-102 Injection in the treatment of high-grade cervical intraepithelial neoplasia (CIN2/3) caused by HPV 16/18/52/58 infection.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
1)The pathology of the target lesion during the screening period confirmed adenocarcinoma, adenocarcinoma in situ (AIS), or invasive carcinoma; 2)of the cervix , vagina , vulva , or anus ; 3)During the screening period, microscopic examination revealed a suspected malignant tumor .
4)Having undergone a total hysterectomy and therefore unable to assess cervical lesions ; 5)excluding cured papillary thyroid carcinoma, basal cell carcinoma of the skin, cervical carcinoma in situ, etc. ) in locations other than those mentioned above within the 5 years prior to enrollment .
9. used continuously (for more than 7 days ) within 30 days prior to screening , including but not limited to: (excluding physiological replacement doses: prednisone ≤10 mg/d or other glucocorticoids at equivalent doses); cyclosporine, tacrolimus, azathioprine, 6-mercaptopurine, methotrexate, etc.
10.Those who have received a known anti-HPV drug (including HPV prophylactic vaccine) within 30 days prior to screening.
11.Those who have previously undergone surgery or physical therapy for high-grade intraepithelial lesions, including but not limited to: loop electrosurgical excision procedure (LEEP), cold knife conization (CKC), laser ablation/resection, cryotherapy, electrocautery, photodynamic therapy, microwave therapy, focused ultrasound therapy, and other invasive/minimally invasive resection or ablation treatments targeting the lesion tissue.
12.A history of severe allergies (requiring hospitalization), a severe reaction to any medication or vaccine injection, or any known or suspected allergy to any component of an investigational drug or preparation.
13.Individuals with uncontrolled systemic chronic diseases. 14.The screening period laboratory tests meet any of the following criteria:
16.Researchers consider participants who are unwilling or unable to comply with the requirements of the research protocol to be experimental participants.
Alternative criteria for trial participants :
To ensure the scientific validity and reliability of the experimental data, supplementary trials may be conducted by recruiting new participants if the following situations occur during the research process :
Exit criteria:
Participants have the right to voluntarily withdraw from the study treatment at any time. Furthermore, the investigator may decide to withdraw a participant from the study treatment if the participant meets the following withdrawal criteria :
For each trial participant who discontinues study treatment , the investigator must record all required details in the electronic case report form (eCRF), including the date and reason for treatment discontinuation. Before withdrawing from the study, trial participants who discontinue study treatment must complete all examinations required for the final visit as specified in the trial protocol and undergo the corresponding follow-up. For all trial participants who withdraw from the study due to adverse events , follow-up must be conducted until the event is resolved, stabilized, returns to baseline levels, is attributable to a cause other than the study drug, or if further information is unavailable. The results must be recorded in the eCRF (and, after database locking, the follow-up results should be recorded in the original files at the research institution).
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: AVL-102 Injection
A total of 3 injections of AVL-102 are to be administered, with an interval of three weeks between each. The drug is to be given via intramuscular injection into the lateral aspect of the upper arm, 2-3 finger-widths below the acromion; each dose should be administered into one of the upper arms. Following each injection, the recipient must remain under observation for 60 minutes, during which time a safety assessment will be conducted.
Dose-limiting toxicities (DLT),incidence and severity of adverse events, etc.
Time frame: Up to day 300
Maximum tolerated dose (MTD) and RDE
Time frame: Up to day 300
Geometric Mean Titer (GMT) of Anti-HPV16/18/52/58 Antigen-Specific Antibodies
Humoral immune response evaluated by measuring serum antigen-specific antibody titers against HPV types 16, 18, 52, and 58 using Enzyme-Linked Immunosorbent Assay (ELISA).
Time frame: Up to day 300
Cell-Mediated Specific Immune Response Against HPV16/18/52/58 Antigens
Cellular immune response evaluated by measuring the number of IFN-γ secreting antigen-specific T cells per million peripheral blood mononuclear cells (PBMCs) using Enzyme-Linked Immunospot (ELISpot) assay, reported as Spot Forming Cells (SFCs)/10\^6 PBMCs.
Time frame: Up to Day 300
Validity
1. The extent of lesion regression as assessed by histopathology at the last visit ; 2. The rate of HPV16/18/52/58 single or multiple virus positivity turning negative at the last visit .
Time frame: Up to day 300
Exploratory endpoint indicators-Pharmacokinetics-Maximum Observed Plasma Concentration (Cmax)
Peak plasma concentration of the study drug measured after administration (Unit: ng/mL)
Time frame: Up to day 43
Exploratory endpoint indicators-Pharmacokinetics-Time to Reach Maximum Observed Plasma Concentration (Tmax)
Time elapsed from drug administration to reach Cmax (Unit: hours).
Time frame: Up to day 43
Exploratory endpoint indicators-Pharmacokinetics-Area Under the Plasma Concentration-Time Curve from Time Zero to the Last Quantifiable Concentration (AUC0-t)
Calculated using the linear trapezoidal method from time 0 to the last measurable concentration time point (Unit: h\*ng/mL).
Time frame: Up to day 43
Exploratory endpoint indicators-Pharmacokinetics-Area Under the Plasma Concentration-Time Curve from Time Zero Extrapolated to Infinity (AUC0-∞)
Calculated as AUC0-t plus the extrapolated area from the last measurable concentration to infinity (Unit: h\*ng/mL).
Time frame: Up to Day 43
Exploratory endpoint indicators-Pharmacokinetics-Terminal Elimination Half-Life (t1/2)
Time required for the plasma concentration of the drug to decrease by 50% during the terminal elimination phase (Unit: hours).
Time frame: Up to Day 43
Exploratory endpoint indicators-Pharmacokinetics-Mean Residence Time (MRT)
Average time the drug molecules stay in the body after administration (Unit: hours).
Time frame: Up to Day 43
Exploratory endpoint indicators-Pharmacokinetics-Total Plasma Clearance (CL)
Volume of plasma from which the drug is completely removed per unit time (Unit: L/h).
Time frame: Up to Day 43
Exploratory endpoint indicators-Pharmacokinetics-Terminal Elimination Rate Constant (λz)
First-order rate constant associated with the terminal (log-linear) portion of the concentration-time curve (Unit: 1/h).
Time frame: Up to Day 43
Exploratory endpoint indicators-Pharmacokinetics-Apparent Volume of Distribution (Vd)
Theoretical volume that would be necessary to contain the total amount of an administered drug at the same concentration that it is observed in the blood plasma (Unit: L).
Time frame: Up to Day 43
Exploratory endpoint indicators-Cytokines
Expression level of IL-1β, IL-2, IL-6, IL-10, GM-CSF, TNF-α and IFN-γ
Time frame: Up to day 300
Exploratory endpoint indicators-PEG antibody
Anti-polyethylene glycol (PEG) antibody response: Serum anti-PEG IgG and anti-PEG IgM titers were measured by enzyme-linked immunosorbent assay (ELISA) to assess the potential association between the immunogenicity of the PEGylated lipid components in LNP and its adverse reactions after repeated administration.
Time frame: Up to day 126
Started Sep 2026 (actual). Primary completion is estimated for Jul 2027, 10 months after the start.
Of 16 phase 1 interventional studies under Papillomavirus Infections, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 25. This study's planned 10 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.